Pharmacophore modeling, design, and synthesis of potent antihypertensives, oxazolo/thiazolo-[3,2-a]-pyrimidin-3(2H)-one, and 1,5-dihydroimidazo-[1,2-a]-pyrimidin-3(2H)-one derivatives: A pilot trial
作者:Manoj Keshari、Riaz A. Khan、Habibullah Khalilullah、Mohammad Yusuf、Bahar Ahmed
DOI:10.1016/j.bmcl.2020.127604
日期:2020.12
synthesize oxazolo/thiazolo-[3,2-a]-pyrimidin-3(2H)-one, and 1,5-dihydroimidazo-[1,2-a]-pyrimidin-3(2H)-one derivatives exhibiting potent anti-hypertensive activity. The 6-ethoxycarbonyl-2,7-dimethyl-5-phenyl-1,5-dihydroimidazo[3,2-a]pyrimidin-3(2H)-one (4g), and 6-ethoxycarbonyl-2,7-dimethyl-5-(3-methyl-phenyl)-1,5-dihydroimidazo[3,2-a]pyrimidin-3(2H)-one (4h) showed significant reduction in mean arterial
改进的药效团模型,分子特性,几何分析和SAR合成了恶唑/噻唑-[3,2-a]-嘧啶-3(2H)-one和1,5-二氢咪唑-[1,2-a] ] -pyrimidin-3(2H)-one衍生物具有有效的抗高血压活性。6-乙氧基羰基-2,7-二甲基-5-苯基-1,5-二氢咪唑并[3,2-a]嘧啶-3(2H)-one(4g)和6-乙氧基羰基-2,7-二甲基- 5-(3-甲基-苯基)-1,5-二氢咪唑并[3,2-a]嘧啶-3(2H)-one(4h)分别显示,在1.5毫克/千克体重的剂量下,平均动脉血压(MABP,mm / Hg)在6和12小时内分别降低了79.78%和92.95%,而在3.0毫克/千克体重下-与标准药物硝苯地平相比,在体重减轻的情况下,在6小时和12小时内MABP分别降低了95.46%和92.02%。